TARA stock forecast
Our latest prediction for Protara Therapeutics, Inc.'s stock price was made on the July 30, 2020 when the stock price was at 25.78$.
In the short term (2weeks), TARA's stock price should underperform the market by -3.34%. During that period the price should oscillate between -13.83% and +15.76%.
In the medium term (3months), TARA's stock price should underperform the market by -4.10%. During that period the price should oscillate between -44.32% and +38.92%.Get email alerts
Create a solid portfolio with TARA
About Protara Therapeutics, Inc.
Protara Therapeutics, Inc. is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman in 2017 and is headquartered in New York, NY.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -2.57$ per share.
The book value per share is 11.08$
Three months stock forecastJuly 30, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|